Arcturus Therapeutics Holdings Inc. 8-K

What Happened
Arcturus Therapeutics Holdings, Inc. filed an 8-K on May 7, 2026 furnishing a press release with the company's financial results for the quarter ended March 31, 2026 and a corporate update. The filing also discloses that Dennis Mulroy was appointed Chief Financial Officer effective May 1, 2026; he will become the company's principal financial officer the day after Arcturus files its Form 10-Q for the quarter ended March 31, 2026. Mr. Mulroy joins from AnaptysBio (CFO July 2020–April 2026) and has prior CFO experience at La Jolla Pharmaceutical and other biotech companies.

Key Details

• Press release and results: furnished as Exhibit 99.1 in the 8-K (filed May 7, 2026) reporting quarterly results for period ended March 31, 2026.
• CFO appointment: Dennis Mulroy, effective May 1, 2026; Board approved April 15, 2026.
• Compensation: annual base salary $520,000 and eligible for up to 40% of base as annual discretionary cash bonus.
• Equity and severance: granted options to purchase 100,000 shares with a four‑year vesting schedule (25% after one year, then monthly over 36 months); if terminated without Cause or for Good Reason, eligible for 12 months base-salary continuation, pro‑rata bonus, and up to 12 months COBRA; enhanced severance and full equity acceleration apply if termination occurs within 18 months after a Change in Control.
• Interim accounting roles: Joe Roberts (interim principal financial officer since Dec 2025) will remain interim principal accounting officer and Controller.

Why It Matters
The 8-K combines Arcturus’s quarterly results disclosure with a significant leadership change at the finance role. For investors, the new CFO brings extensive biotech CFO experience, which may affect financial strategy and reporting. Compensation and option grants create potential future share dilution and defined severance liabilities (noted above). Investors should review the May 7 press release and the upcoming Form 10-Q for the quarter ended March 31, 2026 for the detailed earnings, revenue and financial-condition information.